Equity Securities, FV-NI, Gain (Loss)
Merck & Co. Equity Securities, FV-NI, Gain (Loss) decreased by 55.0% to $168.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 86.7%, from $90.00M to $168.00M. Over 2 years (FY 2021 to FY 2023), Equity Securities, FV-NI, Gain (Loss) shows a downward trend with a -58.0% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
How to read this metric
An increase indicates positive market performance of held securities, while a decrease reflects market volatility or investment underperformance.
Detailed definition
Represents the unrealized or realized gains and losses on equity investments measured at fair value through net income....
Peer comparison
Common in companies with significant treasury or strategic investment portfolios; peers often report this as a non-operating adjustment.
operating_equity_securities_fv_ni_gain_lossHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $280.00M | $683.00M | $405.00M | -$708.00M | -$284.00M | -$371.00M | -$58.00M | $450.00M | -$175.00M | -$33.00M | $100.00M | $143.00M | $56.00M | -$31.00M | $90.00M | $100.00M | $373.00M | $168.00M |
| QoQ Change | — | +143.9% | -40.7% | -274.8% | +59.9% | -30.6% | +84.4% | +875.9% | -138.9% | +81.1% | +403.0% | +43.0% | -60.8% | -155.4% | +390.3% | +11.1% | +273.0% | -55.0% |
| YoY Change | — | — | — | — | -201.4% | -154.3% | -114.3% | +163.6% | +38.4% | +91.1% | +272.4% | -68.2% | +132.0% | +6.1% | -37.1% | +78.6% | >999% | +86.7% |
Equity Securities, FV-NI, Gain (Loss) at Other Companies
Frequently Asked Questions
- What is Merck & Co.'s equity securities, fv-ni, gain (loss)?
- Merck & Co. (MRK) reported equity securities, fv-ni, gain (loss) of $168.00M in Q1 2026.
- How has Merck & Co.'s equity securities, fv-ni, gain (loss) changed year-over-year?
- Merck & Co.'s equity securities, fv-ni, gain (loss) increased by 86.7% year-over-year, from $90.00M to $168.00M.
- What is the long-term trend for Merck & Co.'s equity securities, fv-ni, gain (loss)?
- Over 2 years (2021 to 2023), Merck & Co.'s equity securities, fv-ni, gain (loss) has grown at a -58.0% compound annual growth rate (CAGR), from $1.94B to $342.00M.
- What does equity securities, fv-ni, gain (loss) mean?
- The net gain or loss from changes in the market value of equity investments.